Revenue

How does a MedTech firm win 'Top Workplace' twice? Echosens proves that a mission-driven culture is the ultimate catalyst for innovation and market leadership.

A Swiss firm claims a CHF 480M raise and a $300M tech fund, but a closer look reveals a company with virtually no verifiable corporate footprint.

A breakthrough drug for a rare brain cancer sweeps prestigious international awards, offering patients a new, targeted therapy to delay aggressive treatments.

A breakthrough eco-friendly antioxidant, SA6000, could slash the environmental impact of tires. But can this molecular innovation scale for global impact?

Shipping giant Frontline secures a massive capital-raising mandate, signaling bold moves ahead. What does this mean for global energy and investors?

A new $4.2 billion coastal city in Muscat aims to merge luxury living with a digital economy. Can Oman's 'MAD' project redefine real estate and its future?

TotalEnergies is creating the UK's largest independent oil producer. A bold bet on fossil fuel efficiency or a contradiction to its green energy goals?

After two decades under its visionary founder, Oxford Nanopore taps a commercial scaling expert to lead its next chapter of global growth and market dominance.

With promising clinical data and a streamlined FDA path, a smarter molecule could finally offer a better, more tolerable treatment for idiopathic pulmonary fibrosis.

Bowman Consulting's acquisition of RPT Alliance is a strategic move to solve the energy crisis facing AI and data centers with rapid-deployment power.

Sensorion clears a key safety hurdle for its infant hearing loss gene therapy, but early data reveals a tight race to market against formidable rivals.

OSE Immunotherapeutics is taking back a key drug from AbbVie, betting its own cash on a bigger prize. What does this strategic pivot reveal about pharma R&D?

AsymBio's massive Shanghai facility isn't just about capacity; it's a key move in the high-stakes world of advanced biologic drug production.

New data shows Ascentage Pharma's drug achieves responses where a leading therapy fails, signaling a strategic coup in the high-stakes oncology market.

Fresh off its spin-off, the US metals processor is in talks to acquire a German giant, a move that could reshape the global steel industry.

New 52-week data shows Protagonist and Takeda's drug slashes phlebotomy needs, signaling a major shift in quality of life for polycythemia vera patients.

Emera renewed its C$600M equity program. We dive into the $20B plan driving this move and what it means for the future of energy grids and investors.

AMC sells its Hycroft Mining stake to gold titan Eric Sprott for $24.1M, ending a curious diversification to double down on its core cinema business.

With shareholder approval secured, the HNI-Steelcase merger is set to create a $5.8B powerhouse. But can it deliver on its $120M synergy promise?

A 209kg opium seizure reveals how Canada's billion-dollar investment in AI and intelligence is disrupting sophisticated global drug smuggling networks.